Interference No. 103,613
I.
The prerequisite for a useful recombinant HVT is that the heterologous nucleic acid
sequence is incorporated in a permissive position or region of the genomic HVT sequence,
i.e. a position or region which can be used for the incorporation of a heterologous
sequence without disrupting essential functions of HVT such as those necessary for
infection or replication. Such a region is called an insertion-region. [page 4]
II.
The insertion region disclosed herein . . . begins at the end of an open reading
frame (ORF-1) . . . Said insertion region of about Skb continues through the ORF's 2, 3, 4
and 5. . . DNA sequences corresponding to the insertionregion outlined above can be
applied for the insertion of genes into the HVT genome without disrupting essential
functions of the virus. [page 4-5] (underlying added for emphasis)
III.
In another example significant parts of the ORF-4 and ORF-5 have been deleted from
the HVT genome and replaced by the Bgalactosidase marker gene resulting in recombinant
viruses comparable with recombinant HVT viruses comprising an insertion of the marker gene
in ORF-2 or ORF-3. [page 5] (underlying added for emphasis)
IV.
The heterologous nucleic acid sequence to be incorporated into the HVT genome
according to the present invention can be derived from any source, e.g. viral,
prokaryotic, eukaryotic or synthetic. Said nucleic acid sequence can be derived from a
pathogen, preferably an avian pathogen, which after insertion into the HVT genome can be
applied to induce immunity against disease. Preferably,
8
Page: Previous 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next
Last modified: November 3, 2007